Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-centre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's Monovalent H1N1 Influenza Virus Vaccine in Healthy Adults Aged 18 to < 65 Years.

NCT00938639 is registered in ClinicalTrials.gov with Seqirus as lead sponsor.

NCT NCT00938639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00938639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-centre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's Monovalent H1N1 Influenza Virus Vaccine in Healthy Adults Aged 18 to < 65 Years.
Lead sponsor
Seqirus
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2009
Completion date
March 31, 2010
Enrollment
240 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza caused by the novel influenza a (h1n1) virus